Developmental expression of the CD4 gene in mature T cells is controlled by at least four transcriptional control elements: a promoter, two enhancers and a silencer. In this report we use a transgenic approach to study the mechanisms in which these elements interact to convey appropriate tissue-and cell-specific expression at all stages of T cell development. Our data indicate that the control of CD4 gene expression requires the interaction of multiple elements functioning in different combinations at different stages of T cell development. Expression of the CD4 gene in immature CD4 ⍣ CD8 ⍣ thymocytes requires a third enhancer element located in the 3Ј flanking region of the CD4 gene. Interestingly, the CD4 promoter and proximal/distal enhancers first begin to function at the HSA lo CD69 lo H-2K hi CD4 single-positive stage; cells of this phenotype are believed to have survived positive selection. These data indicate that the CD4 promoter and late enhancer elements are induced by positive selection; thus, the final maturation process is an active event that requires the initiation of a novel program of gene expression.
Introduction
The control of CD4 gene expression provides an excellent T cell development is very complicated; CD4 gene expression is first initiated early in development and is either maintained model system in which to study the molecular events driving T cell development and selection. The expression or lack of in T h cells or turned off in T c cells. The factors that turn CD4 gene expression on and off are believed to be linked both to expression of CD4 and CD8, a similar accessory molecule, is linked directly to each stage of thymic development (for the thymic selection process and to the process that eventually determines the functional subclass of the mature SP T cell review, see 1, 2) . CD4 is first expressed at low levels in early pluripotent hematopoietic stem cells (3) . T cell precursors (14) (15) (16) (17) (18) (19) (20) . We and others have identified multiple transcriptional that first arrive in the thymus from the bone marrow maintain this low level of expression (CD4 lo CD8 -TCR -) (4) . CD4 regulatory elements in the CD4 locus, including a promoter (21-23), two enhancers (24-26) and a transcriptional silencer expression is then down-regulated, resulting in the CD4 -CD8 -thymocyte. These cells subsequently express low levels of (27) (28) (29) . As described above, the expression of CD4 during T cell development and activation is very complex; we were CD8 alone, followed by increasing levels of both CD4 and CD8, and the TCR. These cells, referred to as double-positive therefore interested in studying how these transcriptional control elements interact to control CD4 gene expression (DP or CD4 ϩ CD8 ϩ ) cells, represent the bulk of thymocytes and are the first population of thymocytes to undergo the during these processes. Our previous characterization of the promoter revealed that an enhancer element was necessary receptor-mediated selection processes that are critical for generating the appropriate repertoire of antigen-specific, nonto obtain reporter gene expression in transient transfection experiments using DP thymoma cell lines (21). Here we self-reactive T cells (5-13). The survivors will then downregulate either CD4 or CD8, leading to the mature CD4 ϩ CD8 -demonstrate that the previously identified promoter and enhancer elements are insufficient to induce CD4 expression or CD4 -CD8 ϩ populations (6,7,9,11,13). These latter cells, referred to as the single-positive (SP) T cells, represent in immature DP cells in transgenic mice. There is an uncharacterized control element in the CD4 locus that is capable the mature thymocyte; these cells eventually migrate to the periphery to become helper T cells (T h ) or cytotoxic T cells of inducing CD4 gene expression in immature CD4 ϩ CD8 ϩ thymocytes and in different non-T cell hematopoietic cells. (T c ) respectively. Thus, the temporal expression of CD4 during The CD4 silencer can function on this enhancer to limit and proximal enhancers, the pF and pG constructs contain the following CD4 genomic restriction enzyme fragments: a expression to CD4 ϩ cells; thus this element may represent the putative DP enhancer. In addition, we have conducted a 600 bp PstI-BglII fragment containing DH site 2, a 700 bp KpnI-BstXI containing DH site 4 and a 1.0 kb XhoI-KpnI detailed multiparameter flow cytometric analysis of mice transgenic with constructs lacking the putative DP enhancer fragment containing DH site 5, all from cosmid 2J3. In addition, these constructs contained a 1.7 kb BglII-PstI fragment element(s). Our analysis indicates that the onset of marker expression in these mice does not coincide with the downcontaining the promoter and the entire CD4 first exon, and a 1.2 kb BamHI fragment within the first intron containing a regulation of endogenous CD8; first expression of the marker gene occurs late in development of the CD4 SP T cell. These potential faint DH site not previously identified; these latter fragments were obtained from the J4 cosmid and are condata indicate that control of expression of CD4 in DP and CD4 SP cells requires different elements and that the function tained either within the promoter or the 6 kb XhoI-HindIII first intron fragment used in the cosC and λE constructs (27) . A of the CD4 promoter and distal/proximal enhancers is linked to the successful completion of positive selection. Thus, we splice acceptor site was cloned immediately upstream of the HLA-B7 marker gene in these constructs, thus permitting the believe that the control of CD4 gene expression in vivo requires the interaction of multiple elements functioning in direct splicing of the first CD4 exon to the marker gene. different combinations at different stages of T cell development.
Generation of transgenic mice Transgenic mice were generated using each of the constructs described above using previously published protocols (31).
Methods
Construct DNA was excised from the vectors and purified on Synthesis of transgenic constructs a 10-40% continuous sucrose gradient. Fractions containing the appropriate insert DNA were then pooled and dialyzed For the cosC, λB, pA5UA and pTG transgenic constructs, against injection buffer (0.1 mM EDTA, 5 mM Tris, pH 7.5). restriction enzyme fragments that contained each DNase
The DNA was then sterile-filtered and microinjected into the hypersensitive (DH) site were subcloned into the reporter pronuclei of fertilized mouse eggs obtained from (C57BL/ construct vector using standard techniques [see Fig. 1 ; details 6ϫCBA)F 1 ϫ(C57BL/6ϫCBA)F 1 crosses. The injected eggs of the cosC and λB construct synthesis have been reported were then implanted into Swiss-Webster foster mothers as previously (30) ]. The cosC construct contains all 17 DH sites described previously (31) . Founders were identified using a in the CD4 locus, whereas λB contains DH sites 1-6 and 11-combination of PCR techniques and flow cytometric analysis 17 (27) . The pA5UA construct contains all six DH sites (DH on peripheral blood and by genomic Southern blotting on 1-6) located in the CD4 5Ј flanking region. DH1 was isolated tail DNAs as described previously (29) . Multiple expressing on a 1.3 kb BglII restriction enzyme fragment, and DH2 and founders were analyzed for each construct: we have analyzed DH3 were isolated on a 5 kb SacI restriction enzyme fragment the results from five cosC founders, three λB founders, three from the 2J3 cosmid. The CD4 promoter region containing pA5UA founders, three pTG founders, eight pF and four pG DH sites 4-6 was isolated as a 3.0 kb XhoI restriction enzyme founders ( Fig. 5 and data not shown). The results from one fragment from the J4 cosmid. In addition to the restriction enzyme fragments containing the minimal promoter and distal representative founder for each construct are shown; all other founders were consistent with those presented (data 6B2 (anti-B220); APC-conjugated M1/70 (anti-MAC-1); and FITC-conjugated GK1.5 (anti-CD4). Biotin reagents were not shown).
revealed with a second-step stain of Texas Red-conjugated RNA purification and Northern analyses Avidin from Caltag (South San Francisco, CA). The transgenic marker was stained with ME-1 [anti-HLA-B7 (29)], which was Spleen and thymus tissue were harvested from transgenic mice, and RNA purified as described (32) . Briefly, tissue was revealed by a second-step stain of PE-conjugated polyclonal goat anti-mouse IgG1 from Caltag. homogenized in 2 ml of denaturing solution (4 M guanidinium thiocyanate; 25 mM sodium citrate; 0.1 M β-mercaptoethanol)
The different hematopoietic cell populations were identified using a variety of different combinations of antibodies and using a Fisher Polytron for 1 min at maximum speed. The homogenate was then recovered and the following solutions preparations. The different subclasses of splenic T cells were identified from a whole splenocyte preparation; γδ T cells were added sequentially, with thorough mixing immediately after each addition: 200 µl 2 M sodium acetate (pH 4.0), 1 ml were identified from spleen using anti-CD3 and anti-TCRγδ antibodies; B cells and macrophages were excluded by water-saturated phenol and 1 ml 49:1 chloroform:isoamyl alcohol. The solution was then centrifuged, the aqueous gating out B220 ϩ and Mac-1 ϩ cells. Splenic NK cells were identified using NK1.1 antibodies after gating out TCRαβ ϩ , phase recovered and the RNA precipitated with the addition of 1 volume of isopropyl alcohol. After the recovery of the B220 ϩ and Mac-1 ϩ cells. Mature splenic B cells were identified using B220 and gating out T cells using anti-TCRαβ. RNA by centrifugation, the pellet was resuspended in 300 µl of denaturing solution and reprecipitated with 1 volume of Splenic pre/pro B cells were identified from bone marrow by gating on B220 ϩ IgM -cells. Splenic macrophage and isopropyl alcohol. The RNA pellet was then resuspended in 100 µl DEPC-treated H 2 O. Northern analyses were performed granulocytes were identified using antibodies directed against Mac-1 and Gr-1; T and B cells were gated out using antias described (30) . Ten micrograms of total RNA were resolved on a 1% agarose formaldehyde gel and blotted to nitrocellu-B220 and anti-TCRαβ. Erythroblasts and platelets were identified from bone marrow and peripheral blood respectively; lose and hybridized using either the HLA-B7 cDNA probe or with a murine β-actin cDNA probe.
erythroblasts were identified with TER-119 and side scatter, whereas platelets were identified with 4A5 and forward scatter.
Flow cytometric analyses
For the analysis of the pTG transgenic mice, thymocytes were stained with anti-CD4, anti-CD8, anti-ME-1 and either antiCells were analyzed on a dual-laser FACStar Plus (Becton Dickinson, Mountain View, CA) located at the Columbia CD3, anti-HSA, anti-CD69 or anti-H-2K. For the CD4 SP analysis, the CD8 ϩ thymocytes were gated out, and the Presbyterian Cancer Center. Calibration was performed before each experiment using Fluoricon multi-fluorescent marker-positive and marker-negative populations were then gated and analyzed for CD3, HSA, CD69 or H-2K expression. beads (Baxter Healthcare, McGaw Park, IL) and Shiva, a computer calibration program (Stanford University). A singleSimilarly, for the CD8 SP analysis the CD4 ϩ cells were gated out. color compensation control for each of the four fluorescence channels was prepared for each experiment and compensation was done by eye. Data were collected and analyzed Results using the Electric Desk software package (W. Moore, Stanford University) running on a MicroVax 3400 (Digital Equipment,
The transcriptional control elements in the CD4 locus function Maynard, MA). The 5% probability contour plots contain an in a limited subpopulation of hematopoietic cells equal number of cells at each contour level. Histograms represent the percentage density of cells at a particular Using DH and transgenic assays, we and others have identified many transcriptional control elements in the CD4 locus, fluorescence level, rather than the actual number of cells at each fluorescence level. All plots were gated by propidium including the promoter, two enhancers and a silencer (27, 28) . In addition to the five DH sites that included these four iodide fluorescence to exclude dead cells.
All analyses were performed on 4-to 7-week-old littermates elements, our original transgenic constructs contained 12 other DH sites whose role in CD4 gene expression, if any, is housed in the pathogen-free Cancer Center Animal Facility at Columbia University. The following mAb reagents were unknown ( Fig. 1) . To characterize the role that these DH sites may play in CD4 gene expression, we have generated obtained from PharMingen (San Diego, CA) to identify splenic and thymic cells: allophycocyanin (APC)-conjugated RM4-transgenic constructs that contain different combinations of these DH sites (Fig. 2 ). As we have described previously, the 5 (anti-CD4), FITC-conjugated 53-6.7 (anti-CD8α), biotinconjugated PK136 (anti-NK-1.1), FITC-conjugated H57-597 cosC construct contains all of the DH sites in the CD4 locus, including all four known transcriptional control elements. The (anti-TCRαβ), biotin-conjugated GL3 (anti-TCRγδ), biotin-conjugated TER-119 (anti-erythroid cells), biotin-conjugated RB6-λB construct contains the two enhancers, the promoter, and DH sites 2, 4 and 11-17. The pA5UA construct is identical to 8C5 (anti-Gr-1), biotin-conjugated 145-2C11 (anti-CD3ε), biotin-conjugated AF6-88.5 (anti-H-2K b ), biotin-conjugated λB with the exception of DH sites 11-17, which are not present on the pA5UA construct. The pTG construct contains only 36-7-5 (anti-H-2K k ), biotin-conjugated M1/69 (anti-HSA) and biotin-conjugated H1.2F3 (anti-CD69). FITC-conjugated 4A5 the two enhancers and the promoter. Transgenic mice were generated from each of these con-(anti-platelet cells) was kindly provided by Dr Samuel Burstein (33) . The following monoclonal reagents were made available structs and analyzed for marker gene expression in different tissues and cell types. We have generated and analyzed with the generosity of Dr Alan Stall: FITC-conjugated 331 (anti-IgM); FITC-, phycoerythrin (PE)-and APC-conjugated multiple founders from each transgenic series; typical results data indicate that even in the absence of the silencer the transcriptional control elements in the CD4 locus are sufficient to limit expression of CD4 to the hematopoietic compartment.
To determine the precise specificity of the CD4 locus (Fig. 4) . The cosC and pTGSil transgenic mice did not express constructs and the pTGSil and pTG constructs were first described the marker gene in any CD4 -cell type; these data are elsewhere (27, 29) .
consistent with previous data showing that the CD4 silencer is capable of inhibiting CD4 expression in non-T cells (27) . Interestingly, the λB transgenic mice express the marker gene in many different hematopoietic cell types. These include all from each founder series are shown. Total RNAs were purified from different tissues from each founder transgenic line classes of T cells, including all thymic T cells and γδ T cells. In addition, we can detect expression of the marker gene in obtained and subjected to Northern analyses using cDNAs encoding the HLA-B7 marker cDNA or the endogenous murine both pre/pro B and mature B cells, NK cells, and Mac-1 ϩ macrophages and Mac-1 ϩ Gr-1 ϩ granulocytes. However, we β-actin gene as radioactive probes (Fig. 3 and data not shown). As can be seen in Fig. 3 , for the cosC transgenic cannot detect expression of the marker gene in the 4A5 ϩ megakaryocyte or the TER-119 ϩ erythroid lineages. As the mice we can detect marker gene expression primarily in spleen and thymus; as these are lymphoid organs that contain λB transgenic construct does not contain the silencer, these data indicate that the combination of DH sites on this translarge numbers of T cells, these data are consistent with previous data that indicate that constructs containing the genic construct is capable of driving marker gene expression in a wide variety of different hematopoietic cell types. silencer express the marker gene only in the appropriate T cell subclasses. We can detect marker gene expression
In contrast, mice that are transgenic with constructs that contain only the CD4 promoter and enhancers have a much primarily in spleen and thymus in the λB, pA5UA and pTG transgenic mice (Fig. 3 and data not shown) , indicating that more limited pattern of expression. The pA5UA construct contains the identical 5Ј flanking region DNA as the cosC expression of the marker gene in these mice is limited to lymphoid organs as well. We can detect low levels of expresand λB constructs and differs from λB only in that the latter construct contains DH sites 11-17, which are located in the sion in the lung in the λB transgenic mice. Although it is possible that this expression is the result of ectopic expression far 3Ј flanking region (Figs 1 and 2 ). Transgenic mice containing this construct express the marker gene only in perion lung epithelia, we can also detect Ig κ light chain gene mRNA in these samples and thus we believe this positive pheral αβ and possibly γδ T cells but not in cells in the NK, B cell, myeloid, erythroid or megakaryocytic lineages. These signal to be the result of contaminating blood lymphocytes (data not shown). As mentioned above, the λB, pA5UA and data indicate that there is an additional enhancer region in DH sites 11-17 that is capable of driving expression of CD4 pTG constructs do not contain the silencer; thus, these in this population does not correlate completely to surface TCR αβ or γδ expression. Taken together, these data indicate that there are additional transcriptional control regions not present in the pTG or pTGSil constructs that are responsible for inducing CD4 gene expression in immature T cells.
We presumed that this putative DP enhancer element is present on the cosC and λB transgenic constructs, since we can detect marker expression in DP T cells in mice transgenic for these constructs (Fig. 5) . To localize this enhancer further, we generated and analyzed additional transgenic mice using constructs that contain different combinations of the DH sites that are also present in the λB construct (Figs 1 and 2 ). As mentioned above, the pA5UA construct contains all of the 5Ј flanking region DNA contained in the cosC and λB constructs. As can be seen in Fig. 5 , similar to the pTG series transgenic mice we cannot detect expression of the marker in the DP population. To localize the putative DP enhancer further, we analyzed all of the previous murine CD4 transgenic constructs that have been generated to date by ourselves (27, 29) and other groups (28, 35) , and we have generated additional the previous constructs that contain the smallest amounts of CD4 genomic sequences overlap only in the first intron (Fig.  6 ). To determine if this region contains enhancer activity, we generated additional transgenic constructs (Fig. 2) . The pF in a wide variety of hematopoietic lineages. Similarly, mice transgenic for the pTG construct also express the marker and pG constructs contain all six DH sites identified in the 5Ј flanking region of the CD4 gene, including the two enhancers only in the peripheral T cell lineages; these data indicate that the CD4 enhancers and promoter are capable of functioning and the promoter region. All of the DH sites were included to control for the possibility that the putative DP enhancer in cells of these lineages, and that the additional DH sites in the 5Ј flanking region of the CD4 gene do not appear to play functions indirectly through one of the previously characterized elements. Both the pF and pG constructs contain the a role in the control of CD4 gene expression. intact first CD4 exon, which consists entirely of 5Ј untranslated The CD4 enhancers alone cannot drive CD4 expression in region, and portions of intron sequence that were contained DP thymocytes in all previous transgenic constructs. The splice acceptor site from the 5Ј end of the second CD4 exon was cloned 5Ј to To determine the function of the CD4 promoter and enhancers during early development, thymocytes from each of the the HLA-B7 marker gene; thus, these constructs contain an intron and have maintained the intron/exon structure of the transgenic mice were isolated and analyzed for marker expression in each different developmental subclass (Fig. 5) .
CD4 gene. Transgenic mice were generated with these constructs and multiple founders were obtained and analyzed As we previously reported, the cosC transgenic mice express the marker in the CD4 ϩ CD8 -and CD4 ϩ CD8 ϩ thymocytes (Fig. 5 and data not shown). Both the pF and pG transgenic mice had the same phenotype; surprisingly, we were unable only, whereas the λB transgenic mice, due to the lack of the silencer in the construct, express the marker in all thymocyte to detect marker expression in DP thymocytes in either of these founder lines (Fig. 5 and data not shown). subclasses [ Fig. 5 and (27) ]. The pTG and pTGSil transgenic mice express the reporter marker in both the CD4 -CD8 ϩ and
In contrast to the previously published results and analyses (27, 28, 35) , these data indicate that the DP enhancer is not CD4 ϩ CD8 -SP populations or the CD4 ϩ CD8 -SP populations only respectively; again, the difference reflects the absence present in either the 5Ј flanking region or the first intron. To try to localize the enhancer further we reanalyzed progeny of the silencer in the pTG construct (29) . Interestingly, neither the pTGSil nor the pTG transgenic mice express the marker from all of our founder transgenic mice for marker expression in the thymus. The only transgenic mice in which we detect in the CD4 ϩ CD8 ϩ DP thymocyte population. We have obtained this result with multiple founders and with multiple constructs consistent expression in DP thymocytes in all founders contain either the cosC or λB constructs; these two constructs contain (see below and data not shown); thus we believe that this result reflects the lack of a stage-specific enhancer element in common DH sites 11-17 in the far 3Ј flanking region of the CD4 gene. Deletion of this region results in the loss of (or elements) and is not due to transgene expression variegation as has been seen in other systems (34) . In addition, expression of the marker gene in DP thymocytes (compare the λB construct and the pA5UA construct transgenic mice). these mice do not express the marker in the CD4 -CD8 -double-negative (DN) populations (Fig. 5) . We can detect a As mentioned above, the CD4 silencer can limit the function of this enhancer to CD4 ϩ cells (compare the cosC and λB small marker-positive population seen in the DN populations. The identity of this population is unknown; marker expression transgenic mice). Because this enhancer fulfills all of the functional requirements for the DP enhancer, we believe that Thus, these three antigens are useful for defining late stages of T cell development. this region may be the important controlling element in mediating CD4 gene expression in DP thymocytes.
Thymocytes from pTG transgenic mice were isolated and stained with antibodies against CD4 and CD8 and the antiThe CD4 enhancers initiate function in mature CD4 SP T cells marker antibody ME-1 along with different combinations of the anti H-2K, CD69 and HSA antibodies as described in the In our analyses, we noted that most if not all peripheral SP T cells in all founders expressed high levels of the marker gene.
Methods. We then plotted marker expression in the remaining thymocytes against the expression of either CD4 or CD8, However, expression of the marker on CD4 SP thymocytes in mice that are transgenic for the pTG-based constructs was gated on the marker-negative and marker-positive populations, and determined if these populations are expressing always bimodal, representing subpopulations that both expressed and did not express the marker gene (Fig. 5) . In any of these maturation markers (see Methods for details). As can be seen in Fig. 7 , the entire CD4 SP population, most cases,~50% of the CD4 SP thymocytes expressed the marker, whereas 50% did not. For the transgenic constructs including both the transgenic marker-positive and markernegative populations, express high levels of CD3. However, that did not contain the silencer, we also observed bimodal marker expression in the CD8 SP thymocytes; however, unlike the CD4 SPs are bimodal in expressing HSA, CD69 and H-2K, indicating that this population consists of both mature the CD4 SP thymocytes, there are relatively fewer markernegative CD8 SP thymocytes; indeed, in many cases all of and immature SP cells. Interestingly, the CD4 SP transgenic marker-negative cells are primarily CD69 ϩ HSA ϩ H-2K lo , which the CD8 SP thymocytes are expressing the transgenic marker gene (Fig. 5 and data not shown) . To characterize the SP as discussed above is the phenotype of those SP cells that are undergoing positive selection. In contrast, the CD4 SP populations that are and are not expressing the marker gene further, we have conducted multiple-parameter flow transgenic marker-positive populations are mostly CD69 -HSA -H-2K hi cells, which represent the more mature CD4 cytometric analysis on these cells. Thymocytes obtained from the pTG transgenic mice were analyzed with antibodies SP thymocytes that have recently undergone and survived positive selection. As described above, the marker gene in against HSA, CD69 and the MHC class I molecule H-2K. HSA is expressed on all immature thymocytes and is downthe pTG construct is under the transcriptional control of the CD4 promoter and the proximal and distal enhancers only; regulated late in development in the SP stage (36) . CD69 is an activation marker for mature T cells that is expressed our data thus imply that these elements first become functional late in CD4 SP thymocyte development immediately after the transiently in the CD4 ϩ CD8 lo /early SP CD4 population, possibly as the result of activation of these cells during positive thymocyte successfully survives positive selection. Therefore, these data indicate that the CD4 promoter and enhancer selection (37, 38) . The immature SP thymocyte that presumably survives positive selection then down-regulates CD69; the function is directly linked to thymic positive selection events. We conducted similar analyses on the CD8 SP T cells resting mature SP T cell expresses low levels of CD69 but can be induced to express high levels upon activation with isolated from the pTG transgenic mice thymus (Fig. 7) . Unlike the CD4 SP population, total CD8 SP T cells express both antigen (37, 39) . The MHC class I molecule H-2K is expressed at low levels early in thymic development but is up-regulated high and low levels of CD3, indicating that this population contains a mixture of both mature CD8 SP T cells and at the final maturation stage of the SP thymocyte (40) (41) (42) (43) . multimerization of the human proximal enhancer, Salmon et al. also reported the lack of marker expression in DP thymocytes and HSA CD4 SP thymocytes (35) ; taken together, these results were surprising in light of the results of Sawada and coworkers (24, 28) , who reported that the murine proximal enhancer functions in DP cells in transient transfections and in transgenic mice. These contrasting results may be due to non-overlapping sequences in the different transgenic constructs (27) (28) (29) , interspecies differences (35) or complications arising from the non-physiological state of the multimerized enhancer (35) .
We have localized the putative DP enhancer further by generating additional constructs and transgenic mice. Mice transgenic with constructs that contain all of the restriction fragments in common between all of the published DPexpressing constructs do not express the marker gene in DP thymocytes (constructs pF and pG; Fig. 5 and data not shown). We therefore analyzed the expression of our marker gene in all of our different transgenic mice. We can reliably enhancer in this region that can mediate CD4 gene expression in DP thymocytes. In addition, this enhancer can controlled by the CD4 silencer in that the addition of the silencer to the transgenic construct limits marker expression only to CD4 ϩ the immature CD4 -CD8 lo CD3 -population that serves as the cell types (compare cosC and λB marker expression; Fig. 4 ). immediate precursor to the DP thymocyte stage (1, 44) . The Therefore, this novel enhancer fulfills the functional require-CD8 SP population also consists of a bimodal population of ments of the DP enhancer and thus may play a role in the HSA ϩ and HSA -cells; the HSA ϩ cells consisted almost control of developmental CD4 gene expression. We had entirely of the CD8 SP transgenic marker-negative population, earlier reported expression in DP thymocytes in λE transgenic whereas the HSA -population consisted entirely of the CD8 mice. This construct is identical to pA5UA with the addition SP transgenic marker-positive population (Fig. 7) . The observof first-intron sequences (27) . However, further analyses with ations with the CD3 and HSA analyses are consistent with the additional λE founders have shown inconsistent expression view that the CD8 SP transgenic marker-positive population in this population. We therefore conclude that the λE construct consists of the mature CD8 SP population that will emigrate cannot mediate CD4 expression in DP thymocytes (data to the periphery, whereas the CD8 SP transgenic markernot shown). negative population consists of the immature DP thymocyte precursor. Also consistent with this view is the observation CD4 promoter and enhancer function as a marker for that the CD8SP marker-negative population expresses lower positive selection levels of CD8, which is usually seen in the immature CD4 -As discussed above, mice transgenic with constructs that CD8 lo CD3 -population (Fig. 7) .
contain only the proximal and distal enhancers do not express the marker gene until the SP stage of development. Interestingly, these mice do not express the marker immediately after Discussion commitment to the CD4 SP lineage; our data indicate that the Control of CD4 expression in DP thymocytes CD4 promoter and enhancers first begin to function at a later stage of SP development. In addition, our data indicate that We present evidence for the existence of DP stage-specific enhancer elements in the CD4 locus. The requirement for at the CD4 enhancers are not functional at the initial stage after the DP thymocyte commits to the CD4 SP lineage; specifically, least one DP enhancer element was initially determined using transient transfection analyses; our characterization of the at the CD4 ϩ CD8 -CD3 ϩ HSA ϩ CD69 ϩ H-2K lo ('immature CD4 SP') stage. These elements become functional once the promoter revealed that an enhancer element was necessary to obtain reporter gene expression in the AKR1G1 DP SP T cell matures to the CD4 ϩ CD8 -CD3 ϩ HSA -CD69 -H-2K hi ('mature CD4 SP') stage. Bendelac and colleagues (37) thymoma cell line (21). In addition, we determined that the CD4 promoter and distal/proximal enhancers were insufficient have proposed that the transient expression of CD69 in the immature CD4 SP population is the result of intrathymic to drive marker expression in DP thymocytes of transgenic mice (29) . Using a transgenic construct containing the human activation that may be occurring due to the positive selection process; thus, this cell-surface marker can be used to distin-CD4 promoter and a synthetic enhancer containing a 3-fold guish the specific thymocyte population that is undergoing in generating populations of thymocytes at stages both before and after positive selection for biochemical analyses. this important developmental event. In addition, as mentioned above HSA and MHC class I surface expression can also be Control of CD4 gene expression requires multiple elements used to identify these different developmental stages within functioning at different stages during T cell development the CD4 SP thymocyte population (for a complete discussion of these issues, see 43) .
Our data indicate that the control of CD4 gene expression is From the comparisons of our data with those of Bendelac extremely complex. Based on our results we can devise a (37), we propose that the CD4 transcriptional control elements model to account for the control of CD4 expression at all are intimately linked to the thymic selection process. Early in stages of T cell development (Fig. 8) . At early stem-cell T cell development, the CD4 silencer functions to inhibit stages, the low level of CD4 expression is mediated primarily enhancer function in the DN thymocytes. Upon maturation to by the DP enhancer and the silencer. In DN thymocytes, the the DP stage, the silencer stops functioning and a DP DP enhancer is still capable of functioning, but the CD4 enhancer element or elements initiate(s) function, thus permittsilencer inhibits its action and thus CD4 expression is turned ing expression of CD4. The DP thymocyte then undergoes off. Once the DN thymocyte matures into the DP thymocyte, both negative and positive selection; T cells that survive the silencer ceases function and CD4 expression is then positive selection develop first into the immature CD4 SP and mediated once again by the DP enhancer. The down-regulasubsequently to the mature CD4 SP stage. It is during this tion of CD4 during development of the CD8 SP T cell is latter transition that the DP enhancer ceases function and is accomplished primarily by the CD4 silencer. However, the replaced by the CD4 distal and proximal enhancers; in maintenance of CD4 expression as the DP thymocyte conjunction with the promoter, these elements then maintain becomes a CD4 SP T cell requires multiple steps. First, the CD4 expression in mature CD4 SP T cells. Since our pTG DP enhancer remains functional as the CD4 SP T cell downconstructs contain the distal and proximal enhancers but not regulates CD8; thus, the early CD4 SP T cell undergoing the putative DP enhancer, the onset of marker expression in selection (the CD69 ϩ HSA ϩ H-2K lo CD4 SP cell) is transcribing the CD4 SP thymocytes in these mice correlates to a CD4 SP the CD4 gene primarily because of the action of the DP developmental stage immediately following positive selection enhancer. However, once the CD4 SP T cell completes the and before the final maturation of the T lymphocyte. These selection process (the CD69 -HSA -H-2K hi CD4 SP cell), the data have several interesting implications. These data imply DP enhancer ceases to function and the proximal and distal that the maturation of the CD4 SP T cell is an active process enhancers concomitantly begin function and subsequently that involves the initiation of expression of a battery of mediate CD4 gene transcription in resting mature CD4 SP T transcription factors that activate the CD4 promoter and cells. Finally, CD4 promoter function can be induced in proximal/distal enhancers and possibly other genes important activated mature CD4 SP T cells, possibly as a mechanism in mature T cell function (37) . The recovery from positive transiently to increase CD4 expression to compensate for selection, therefore, is not a passive event but rather part of the down-regulation of surface CD4 during the activation an overall developmental program (see Discussion below).
process (23) . These data also indicate that the function of the CD4 promoter Our data indicate that although the surface expression of and enhancers is linked directly to distinct steps in thymocyte CD4 is maintained at a relatively invariant level from the DP cell to the CD4 SP T cell, the transcription of the CD4 gene development. This transgenic system may therefore be useful
